{"title":"Enhancing accuracy in proton therapy: The impact of geometric uncertainty models in head and neck cancer treatment.","authors":"Ying Zhang, Mark Ka Heng Chan","doi":"10.1002/mp.17698","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Anatomical changes present a major source of uncertainty in head and neck (H&N) cancer treatment. Accurate modeling of these changes is important for enhancing treatment precision and supporting better outcomes.</p><p><strong>Purpose: </strong>The purpose of this study is to assess different anatomical uncertainty modeling methods in robust optimization for H&N cancer proton therapy.</p><p><strong>Methods: </strong>This retrospective study involved five nasopharynx radiotherapy patients. We compared conventional robust optimization with anatomical robust optimization (aRO): (1) conventional robust optimization (cRO-3 mm), which used 3 mm setup shift and 3% range uncertainty. (2) aRO_AM which used three predicted images from an AM capturing systematic anatomical changes, with a 1 mm setup shift and 3% range uncertainty. (3) aRO_PM, which used three predicted images from a probability model (PM) capturing the most probable deformations, also with a 1 mm setup shift and 3% range uncertainty. We assessed weekly dose coverage of the clinical target volumes (CTVs). Normal tissue complication probability (NTCP) for grade <math><semantics><mo>≥</mo> <annotation>$\\ge$</annotation></semantics> </math> 2 xerostomia and grade <math><semantics><mo>≥</mo> <annotation>$\\ge$</annotation></semantics> </math> 2 dysphagia were calculated using the accumulated nominal dose (without errors).</p><p><strong>Results: </strong>aRO_PM outperformed cRO-3 mm and aRO_AM, consistently achieving V94 <math> <semantics><msub><mrow></mrow> <mtext>voxmin</mtext></msub> <annotation>$_{\\text{voxmin}}$</annotation></semantics> </math> <math><semantics><mo>≥</mo> <annotation>$\\ge$</annotation></semantics> </math> 95% for all cases across treatment weeks. Additionally, aRO_PM reduced the NTCP for grade <math><semantics><mo>≥</mo> <annotation>$\\ge$</annotation></semantics> </math> 2 xerostomia by an average of 4.88 %, with a maximum reduction of 8.03%, and reduced the NTCP for grade <math><semantics><mo>≥</mo> <annotation>$\\ge$</annotation></semantics> </math> 2 dysphagia by an average of 1.80%, with a maximum reduction of 4.23 %.</p><p><strong>Conclusion: </strong>The PM demonstrates potential for improving robust optimization by effectively managing anatomical uncertainties in H&N cancer proton therapy, thereby enhancing treatment effectiveness.</p>","PeriodicalId":94136,"journal":{"name":"Medical physics","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical physics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/mp.17698","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Anatomical changes present a major source of uncertainty in head and neck (H&N) cancer treatment. Accurate modeling of these changes is important for enhancing treatment precision and supporting better outcomes.
Purpose: The purpose of this study is to assess different anatomical uncertainty modeling methods in robust optimization for H&N cancer proton therapy.
Methods: This retrospective study involved five nasopharynx radiotherapy patients. We compared conventional robust optimization with anatomical robust optimization (aRO): (1) conventional robust optimization (cRO-3 mm), which used 3 mm setup shift and 3% range uncertainty. (2) aRO_AM which used three predicted images from an AM capturing systematic anatomical changes, with a 1 mm setup shift and 3% range uncertainty. (3) aRO_PM, which used three predicted images from a probability model (PM) capturing the most probable deformations, also with a 1 mm setup shift and 3% range uncertainty. We assessed weekly dose coverage of the clinical target volumes (CTVs). Normal tissue complication probability (NTCP) for grade 2 xerostomia and grade 2 dysphagia were calculated using the accumulated nominal dose (without errors).
Results: aRO_PM outperformed cRO-3 mm and aRO_AM, consistently achieving V94 95% for all cases across treatment weeks. Additionally, aRO_PM reduced the NTCP for grade 2 xerostomia by an average of 4.88 %, with a maximum reduction of 8.03%, and reduced the NTCP for grade 2 dysphagia by an average of 1.80%, with a maximum reduction of 4.23 %.
Conclusion: The PM demonstrates potential for improving robust optimization by effectively managing anatomical uncertainties in H&N cancer proton therapy, thereby enhancing treatment effectiveness.